HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 4, 2015, Pages 377-385

  Côrtes, Fernanda H ^a   Passaes, Caroline P B ^a,d,e   Bello, Gonzalo ^a   Teixeira, Sylvia L M ^a   Vorsatz, Carla ^b   Babic, Dunja ^c   Sharkey, Mark ^c   Grinsztejn, Beatriz ^b   Veloso, Valdilea ^b   Stevenson, Mario ^c   Morgado, Mariza G ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d INSTITUT PASTEUR   (France)

^e DIF   (France)

Author keywords

elite controllers; HIV 1; immune activation and microbial translocation; immune response; ongoing replication; viral load blips

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; GAG PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; NEF PROTEIN; VIRUS DNA; VIRUS RNA;

ADULT; ANTIBODY RESPONSE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC PARAMETERS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; MALE; MIDDLE AGED; OPTICAL DENSITY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; HIV SURVIVOR; IMMUNOLOGY; ISOLATION AND PURIFICATION; VIROLOGY;

ADULT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; MALE; VIRAL LOAD;

EID: 84924517942     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000500     Document Type: Conference Paper

References (43)

1. Madec Y, Boufassa F, Porter K, et al. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS. 2005;19:2001-2007
2. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-Term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009;200: 1714-1723
3. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41:1053-1056
4. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197:563-571
5. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009;23:897-906
6. Saez-Cirion A, Sinet M, Shin SY, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol. 2009;182:7828-7837
7. Bello G, Velasco-de-Castro CA, Bongertz V, et al. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1. J Med Virol. 2009;81:1681-1690
8. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126-133
9. Andrade A, Bailey JR, Xu J, et al. CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B 5801-positive patient with an undetectable viral load. Clin Infect Dis. 2008;46:e78-e82
10. Sedaghat AR, Rastegar DA, O'Connell KA, et al. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis. 2009;49:1763-1766
11. Williams LD, Bansal A, Sabbaj S, et al. Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers. J Virol. 2011;85:2316-2324
12. Betts M, Nason M, West S, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107: 4781-4789
13. Owen RE, Heitman JW, Hirschkorn DF, et al. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS. 2010;24:1095-1105
14. Hersperger AR, Pereyra F, Nason M, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010;6:e1000917
15. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A. 2007;104:6776-6781
16. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B 5701 is highly associated with restriction of virus replication in a subgroup of HIVinfected long term nonprogressors. Proc Natl Acad Sci U S A. 2000;97: 2709-2714
17. Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010; 330:1551-1557
18. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007;317:944-947
19. Emu B, Sinclair E, Hatano H, et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for longterm virus control. J Virol. 2008;82:5398-5407
20. Cortes FH, Bello G, Vorsatz C, et al. Higher cross-subtype IFN-gamma ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- And F1- Than in C-infected subjects. Vaccine. 2013;31:1106-1112
21. Passaes CP, Bello G, Lorete RS, et al. Genetic characterization of HIV-1 BC recombinants and evolutionary history of the CRF31-BC in Southern Brazil. Infect Genet Evol. 2009;9:474-482
22. Teixeira SL, Bastos FI, Hacker MA, et al. Distribution of CCR5 genotypes and HLA Class I B alleles in HIV-1 infected and uninfected injecting drug users from Rio de Janeiro, Brazil. Infect Genet Evol. 2009;9:638-642
23. Sharkey M, Babic DZ, Greenough T, et al. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog. 2011;7:e1001303
24. Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses. 2002;18:295-307
25. Calarota SA, Foli A, Maserati R, et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol. 2008;180:5907-5915
26. Epi Info [computer program]. Version 6: A Word Processing, Database, and Statistics Program for Epidemiology on Microcomputers. Atlanta, GA: Centre for Disease Control and Prevention; 1995
27. Velasco-de-Castro CA, Grinsztejn B, Veloso VG, et al. HIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, Brazil. PLoS One. 2014;9:e87622
28. Teixeira SL, de Sa NB, Campos DP, et al. Association of the HLA-B 52 allele with non-progression to AIDS in Brazilian HIV-1-infected individuals. Genes Immun. 2014;15(4):256-62
29. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-188
30. Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog. 2011;7: e1001300
31. Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009;200:984-990
32. Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2009;83:329-335
33. Mens H, Kearney M, Wiegand A, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol. 2010;84: 12971-12981
34. O'Connell KA, Brennan TP, Bailey JR, et al. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol. 2010;84:7018-7028
35. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS. 2012;26:2409-2412
36. Klatt NR, Chomont N, Douek DC, et al. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013;254:326-342
37. Boufassa F, Saez-Cirion A, Lechenadec J, et al. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One. 2011;6:e18726
38. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18:981-989
39. Migueles S, Osborne C, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008;29:1009-1021
40. Tomescu C, Duh FM, Hoh R, et al. Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. AIDS. 2012;26:1869-1878
41. Lecuroux C, Saez-Cirion A, Girault I, et al. Both HLA-B 57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. J Virol. 2014;88:176-187
42. Hayashida T, Gatanaga H, Tanuma J, et al. Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses. 2008;24:495-498
43. Wendel SK, Mullis CE, Eshleman SH, et al. Effect of natural and ARVinduced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One. 2013;8:e55525